Urinary Fetuin-A Is a Novel Marker for Diabetic Nephropathy in Type 2 Diabetes Identified by Lectin Microarray

Kentaro Inoue1, Jun Wada1, Jun Eguchi1, Atsuko Nakatsuka1, Sanae Teshigawara1, Kazutoshi Murakami1, Daisuke Ogawa1, Takahiro Terami1, Akihiro Katayama1, Atsuhito Tone4, Izumi Iseda4, Kazuyuki Hida4, Masao Yamada5, Tomohisa Ogawa6, Hirofumi Makino1

1 Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kita-ku, Okayama, Japan, 2 Department of Diabetic Nephropathy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kita-ku, Okayama, Japan, 3 Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kita-ku, Okayama, Japan, 4 National Hospital Organization Okayama Medical Center, Department of Diabetes and Metabolism, Kita-ku, Okayama, Japan, 5 GlycoTechnica Ltd., Aoba-ku, Yokohama, Japan, 6 GP BioSciences Co., Ltd., Aoba-ku, Yokohama, Japan

Abstract

We analyzed the urine samples of patients with type 2 diabetes at various stages of diabetic nephropathy by lectin microarray to identify a biomarker to predict the progression of diabetic nephropathy. Japanese patients with type 2 diabetes at various stages of nephropathy were enrolled and we performed lectin microarray analyses (n = 17) and measured urinary excretion of fetuin-A (n = 85). The increased signals of urine samples were observed in Sia2-6Gal/GalNAc-binding lectins (SNA, SSA, TJA-I) during the progression of diabetic nephropathy. We next isolated sialylated glycoproteins by using SSA-lectin affinity chromatography and identified fetuin-A by liquid chromatography–tandem mass spectrometer. Urinary excretion of fetuin-A significantly increased during the progression of albuminuria (A1, 0.40 ± 0.43; A2, 0.60 ± 0.53; A3 1.57 ± 1.13 ng/gCr; p = 7.29 × 10^-9) and of GFR stages (G1, 0.39 ± 0.39; G2, 0.49 ± 0.45; G3, 1.25 ± 1.18; G4, 1.34 ± 0.80 ng/gCr; p = 3.89 × 10^-3). Multivariate logistic regression analysis was employed to assess fetuin-A as a risk for diabetic nephropathy with microalbuminuria or GFR < 60 mL/min. Fetuin-A is demonstrated as a risk factor for both microalbuminuria and reduction of GFR in diabetic nephropathy with the odds ratio of 4.721 (1.881–11.844) and 3.739 (1.785–7.841), respectively. Collectively, the glycan profiling analysis is useful method to identify the urine biomarkers and fetuin-A is a candidate to predict the progression of diabetic nephropathy.

Introduction

The most critical issue in clinical nephrology is relentless and progressive increase in the patients with end-stage renal disease (ESRD) in worldwide. The impact of diabetic nephropathy on the increasing population with chronic kidney disease (CKD) and ESRD is enormous. The intensified multifactorial intervention in patients with type 2 diabetes mellitus resulted in reduced risk of microangiopathy, cardiovascular events and mortality in Steno type 2 randomized studies [1]; however, the incidence of ESRD is progressively increasing in worldwide. To predict the progression of diabetic nephropathy and cardiovascular outcome, the simultaneous evaluation of albuminuria and glomerular filtration rate (GFR) is recommended by the KDIGO: Kidney Disease Improving Global Outcomes CKD Work Group [2]. In The Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) study, the measurements of albuminuria, eGFR or their combination predicted the cardiovascular events and death, and renal outcome [3]. In addition to the albuminuria at baseline, the changes of albuminuria further well-predicted mortality and cardiovascular and renal outcomes, independent of baseline albuminuria reported by ONTARGET investigators [4]. Although the repeated measurements of albuminuria is recommended in the clinical practice in diabetes, the presence of GFR decliners in both type 1 and type 2 diabetes has been reported. In type 1 diabetes, the GFR decliners with early reduction of GFR were reported in 9% of the patients with normoalbuminuria and 31% of microalbuminuria [5]. In the patients with type 2 diabetes, the rapid GFR decliners demonstrated the reduction of GFR although they were treated with olmesartan in addition to the angiotensin converting enzyme inhibitors. In such patients, it was difficult to predict the natural course of diabetic nephropathy by the combination of albuminuria and eGFR [6].
Based upon these clinical observations, we need to search more reliable urinary biomarkers to predict both renal and cardiovascular outcome. The biomarkers of renal dysfunction such as transferrin, type IV collagen and N-acetyl-β-D-glucosaminidase,

Table 1. A list of lectins of LecChip™Ver.1 and the specificity.

| Lectin No. | Lectin Origin | Reported specificity |
|------------|---------------|----------------------|
| 1          | LTL Lotus tetragonolobus | Fuc α1-3(Gal|β1-4)GlcNAC, Fuc α1-2Gal|β1-4GlcNAC |
| 2          | PSA Pisum sativum | Fuc α1-6GlcNAC, α-D-Glc, α-D-Man |
| 3          | LCA Lens culinaris | Fuc α1-6GlcNAC, α-D-Glc, α-D-Man |
| 4          | UEA-I Ulex europaeus | Fuc α1-2Gal|β1-4GlcNAC |
| 5          | ALO Aspergillus oryzae l-fucose-specific lectin | Fuc α1-6GlcNAC (core fucose) |
| 6          | AAL Aleuria aurantia | Fuc α1-6GlcNAC, Fuc α1-3(Gal|β1-4)GlcNAC |
| 7          | MAL Maackia amurensis | Siaα2-3Gal|β1-4GlcNAC |
| 8          | SNA Sambucus nigra | Siaα2-6Gal/GalNAc |

These data were collected from lectin vendors and reports found by internet searches.

doi:10.1371/journal.pone.0077118.t001
inflammatory markers including orosomucoid, tumour necrosis factor-2, transforming growth factor-β, vascular endothelial growth factor and monocyte chemoattractant protein-1, as well as oxidative stress markers such as 8-hydroxy-2′-deoxyguanosine may be more sensitive than urinary albumin, the current gold standard, in the detection of incipient nephropathy and risk assessment of cardiovascular disease; however, the sensitivity of these markers compared with albumin requires further investigation [7].

Recently, the urinary proteome analyses have been performed using 2-dimensional gel electrophoresis and subsequent mass spectrometry to identify the novel urinary markers [8–10]; however, the identification of new markers may be suffered from contamination of urinary major proteins such as albumin, immunoglobulins, α1-antitrypsin, transferrin, and haptoglobin. In the line of considerations, we focused on the alterations of glycochains to identify useful urinary biomarkers. The changes in glycoproteome profile in the urine may be due to the alterations in the glycoprotein leakage into the urine by the damages of capillary selective permeability and also attributed to the high glucose-induced changes in the expression of the enzymes which are responsible to the glycochain modification. For example, increased hexosamine biosynthesis induced by high glucose conditions plays a key role in the development of insulin resistance in primary cultured adipocytes [11] and the increased flux through the hexosamine biosynthetic pathway and subsequent enhanced O-linked glycosylation (N-acetylglucosamine [O-GlcNAc]) of proteins have been implicated in insulin resistance in skeletal muscle [12]. However, the glycoproteome profile has not been well-investigated because of the technical obstacles. We employed the evanescent-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling, which allows sensitive, real-time observation of multiple lectin-carbohydrate interactions under equilibrium conditions, to identify the changes in the functional glycans in a high-throughput manner [13]. We identified the increase in the binding activity to Siaα2-6-Gal/GalNAc in urine samples from the patients with diabetic nephropathy. We next identified fetuin-A, α1-microglobulin, and orosomucoid as sialylated glycoproteins and we found fetuin-A may be a useful urinary marker to predict the development of microalbuminuria and reduction of GFR in diabetic nephropathy.

**Materials and Methods**

**Patients**

Urine samples of Japanese healthy subjects without type 2 diabetes (n = 12) and Japanese patients with type 2 diabetes with various stages of normoalbuminuria (n = 7), microalbuminuria (n = 5) and macroalbuminuria (n = 5) were obtained and subjected to lectin microarray studies. Based on the lectin microarray studies, we identified sialylated glycoproteins, such as fetuin-A, α1-microglobulin, and orosomucoid as candidate markers for diabetic nephropathy and we newly recruited Japanese patients with type 2 diabetes (n = 85, 62.9 ± 11.3 years) into this study. The patients with type 2 diabetes were treated with oral hypoglycemic agents (n = 48) and insulin treatment (n = 49). The patients with eGFR < 15 ml/min/1.73 m² or under dialysis were excluded from the current study. All recruited patients with type 2 diabetes agreed to perform lectin microarray of urine samples and measure urinary levels of fetuin-A, α1-microglobulin, and orosomucoid. The study was conducted in accordance with the ethical principle of the Declaration of Helsinki and approved by ethical committee of

**Figure 1. Lectin microarray analysis using urine samples from the patients with various albuminuria stages.** Lectin microarray analysis of urine samples were performed in the healthy subjects without type 2 diabetes (Control, n = 12) and the patients with type 2 diabetes with various stages of normoalbuminuria (A1, n = 7), microalbuminuria (A2, n = 5) and macroalbuminuria (A3, n = 5). Signals to various lectins are compared by Kruskal-Wallis test.

doi:10.1371/journal.pone.0077118.g001
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We obtained written informed consent from each patient.

**Lectin Microarray**

Fifty mL of urine samples were concentrated by Centricon at 5,000 \( g \) for 40 min and further by Microcon at 14,000 \( g \) for 70 min to the volume of 0.5 mL (Millipore, Billerica, MA). Ten mL of concentrated urine samples were applied to Multiple Affinity Removal Spin Cartridge for Human Serum (Agilent Technologies, Santa Clara, CA) to remove major serum proteins such as albumin, IgG, \( \alpha1 \)-antitrypsin, IgA, transferrin, and haptoglobin. Five hundred mL of the effluents dialyzed against PBS were applied to ULTRAFREE 0.5 BIOMAX-5k (Millipore) and concentrated to final volume of 50 mL. Protein concentration was measured with MicroBCA Protein Assay Kit (Thermo Scientific Pierce).

**Figure 2. SSA-Agarose column chromatography performed in the 4 patients with type 2 diabetes. A.** The concentrated urine samples were applied to SSA-Agarose column, washed with PBS and eluted with 0.2 M lactose. **B.** The effluents from the patients manifested with various albuminuria and GFR stages, A3G3 and A3G4, were subjected to SDS-PAGE and stained with Coomassie Brilliant Blue. The bands were visualized and they were subjected to liquid chromatography-tandem mass spectrometer (LC/MS-MS) analysis.

doi:10.1371/journal.pone.0077118.g002

**Table 2.** Liquid chromatography–tandem mass spectrometer (LC/MS-MS) of samples from the patients with A3G3 and the search result through NCBInr and Swiss-Prot database performed by Mascot.

| Pos. | Ac. No.        | Protein Name                 | Sequences | emPAI*1 | Score*2 |
|------|----------------|------------------------------|-----------|---------|---------|
| 1    | ALBU_HUMAN     | Serum albumin                | 36        | 11.04   | 3985    |
| 2    | TRFE_HUMAN     | Serotransferrin              | 15        | 1.08    | 965     |
| 3    | AMBP_HUMAN     | Protein AMBP (alpha 1-microglobulin) | 5 | 0.57 | 224 |
| 4    | VTDB_HUMAN     | Vitamin D-binding protein    | 3         | 0.14    | 130     |
| 5    | HEMO_HUMAN     | Hemopexin                    | 3         | 0.23    | 112     |
| 6    | PTGDS_HUMAN    | Prostaglandin-H2 D-isomerase | 1         | 0.18    | 75      |
| 7    | IGKC_HUMAN     | Ig kappa chain C region      | 1         | 0.34    | 70      |
| 8    | HPT_HUMAN      | Haptoglobin                  | 3         | 0.17    | 63      |
| 9    | DTX3L_HUMAN    | E3 ubiquitin-protein ligase DTX3L | 1 | 0.04 | 49 |
| 10   | CLUS_HUMAN     | Clusterin                    | 1         | 0.07    | 39      |
| 11   | SAP_HUMAN      | Proactivator polypeptide     | 1         | 0.06    | 34      |
| 12   | A1AT_HUMAN     | Alpha-1-antitrypsin          | 2         | 0.08    | 33      |
| 13   | AFAM_HUMAN     | Afamin                       | 2         | 0.05    | 32      |
| 14   | FETUA_HUMAN    | Alpha-2-HS-glycoprotein (Fetuin-A) | 1  | 0.09 | 29 |
| 15   | THRBB_HUMAN    | Prothrombin                  | 1         | 0.05    | 25      |
| 16   | TRPC4_HUMAN    | Short transient receptor potential channel 4 | 1 | 0.03 | 20 |
| 17   | RABE1_HUMAN    | Q15276                       | 2         | 0.04    | 19      |
| 18   | MARK1_HUMAN    | Serine/threonine-protein kinase MARK1 | 1 | 0.04 | 16 |

*emPAI (Exponentially Modified Protein Abundance Index) is calculated for the estimation of absolute protein amount as follow: \( \text{emPAI} = \frac{\text{Observed}}{\text{Observable}} \).

**Probability Based Mowse Score. Ions score is \(-10^\text{Log}(P)\), where P is the probability that the observed match is a random event. Individual ions scores >16 indicate identity or extensive homology (p<0.05).**

doi:10.1371/journal.pone.0077118.t002
Rockford, IL) and the final concentration was adjusted to 50 µg/mL, in which 20 µL was incubated with Cy3 at room temperature for 1 hour. Cy3-labeled samples were applied to gel filtration columns (Zeba Desalt Spin Columns 0.5 ml, Thermo Scientific Pierce) and the samples with 2, 1, 0.5, 0.25, 0.125, 0.063, 0.031 mg/mL were prepared with Probing Buffer and 100 µL of wells of samples were applied to Lectin Array, LecChip (GP Biosciences, Tokyo, Japan) at 20°C for 15 hours. The lectin signals were measured with Glycostation™ Reader 1200 with exposure time (133 msec) and gain (85, 95, 105, and 115). Scanned images of 16 bit TIFF were analyzed with Array-Pro Analyzer (MEDIA CYBERNETICS, Rockville, MD) and GlycoStation Tools (GP Biosciences). The list of lectins is indicated in the Table 1 and blood group A antigen (HPA) and group B antigen (EEL) were excluded from the analysis.

Isolation of Sialylated Urinary Proteins in the Patients with Diabetic Nephropathy

Hundred mL of urine samples were concentrated by Centricon at 5,000 g for 40 min and further by Microcon at 14,000 g for 70 min to the volume of 1 mL. Affinity chromatography was performed using SSA-Agarose (Lectin-Agarose Set-III) and BioLogic LP system II (#731-8300X2, BIO-RAD, Hercules, CA). The SSA-Agarose column was equilibrated by 6.0 mL of PBS at the flow rate of 0.2 mL/min. The concentrated urine samples of 1.0 mL were applied to the sample loop and PBS was loaded at 0.1 mL/min for 10 min. The SSA-Agarose column was washed with PBS at 0.1 mL/min for 70 min. Five mL of the elution buffer (0.2 M lactose) was applied to sample loop and eluted with PBS at 0.5 mL/min for 20 min. While eluting the sialylated glycoproteins, the fractions of 0.5 ml were collected every 5 min. The eluted samples were subjected to SDS-PAGE analysis and the proteins were identified by Liquid chromatography–tandem mass spectrometer (LC/MS-MS) analyses as follows.

Cysteine bonds of the eluted glycoproteins were reduced by 10 mM dithiothreitol (DTT) at 56°C for 1 hour and alkylated with 50 mM iodoacetamide (IAA) at room temperature for 45 min in the dark. They were enzymatically digested with 0.1 mg sequencing grade trypsin at 30°C for overnight. The digested proteins were subjected to LC/MS analyses as follows.

| Pos. | Ac.No. | Protein Name | Sequences | emPAI*1 | Score*2 |
|------|--------|--------------|-----------|---------|---------|
| 1    | ALBU_HUMAN | Serum albumin | 52        | 21.13   | 3829    |
| 2    | TRFE_HUMAN | Serotransferrin | 23        | 1.61    | 800     |
| 3    | HPT_HUMAN | Haptoglobin | 17        | 3.1     | 683     |
| 4    | IGHG1_HUMAN | Ig gamma-1 chain C region | 10 | 2.56 | 601 |
| 5    | IGHG2_HUMAN | Ig gamma-2 chain C region | 8 | 0.99 | 227 |
| 6    | IGKC_HUMAN | Ig kappa chain C region | 6 | 4.73 | 516 |
| 7    | IGHA1_HUMAN | Ig alpha-1 chain C region | 10 | 1.54 | 422 |
| 8    | A2MG_HUMAN | Alpha-2-macroglobulin | 18 | 0.46 | 417 |
| 9    | A1AT_HUMAN | Alpha-1-antitrypsin | 10 | 1.16 | 392 |
| 10   | APOA1_HUMAN | Apolipoprotein A-I | 8 | 1.53 | 251 |
| 11   | AMBP_HUMAN | Protein AMBP (alpha 1-microglobulin) | 7 | 0.88 | 226 |
| 12   | HEMO_HUMAN | Hemopexin | 7 | 0.62 | 214 |
| 13   | LAC2_HUMAN | Ig lambda-2 chain C regions | 4 | 1.45 | 204 |
| 14   | COA4_HUMAN | Complement C4-A | 2 | 0.04 | 147 |
| 15   | CERU_HUMAN | Ceruloplasmin | 2 | 0.06 | 127 |
| 16   | ICT1_HUMAN | Plasma protease C1 inhibitor | 4 | 0.22 | 94 |
| 17   | A1BG_HUMAN | Alpha-1B-glycoprotein | 1 | 0.07 | 94 |
| 18   | PTGDS_HUMAN | Prostaglandin-H2 D-isomerase | 1 | 0.18 | 94 |
| 19   | A1AG1_HUMAN | Alpha-1-acid glycoprotein 1 (orosomucoid) | 3 | 0.56 | 82 |
| 20   | ANGT_HUMAN | Angiotensinogen | 1 | 0.07 | 74 |
| 21   | ANT3_HUMAN | Antithrombin-III | 2 | 0.07 | 72 |
| 22   | RNGL1_HUMAN | Kininogen-1 | 2 | 0.05 | 71 |
| 23   | FETUA_HUMAN | Alpha-2-HS-glycoprotein (Fetuin-A) | 1 | 0.09 | 70 |
| 24   | PGRPA_HUMAN | N-acetylmuramoyl-L-alanine amidase | 1 | 0.06 | 62 |
| 25   | CO3_HUMAN | Complement C3 | 5 | 0.02 | 55 |
| 26   | THR8_HUMAN | Prothrombin | 1 | 0.05 | 31 |
| 27   | VTDH_HUMAN | Vitamin D-binding protein | 1 | 0.07 | 30 |
| 28   | MTSU1_HUMAN | Microtubule-associated tumor suppressor 1 | 1 | 0.03 | 26 |

*1 emPAI (Exponentially Modified Protein Abundance Index) is calculated for the estimation of absolute protein amount as follow: \(\text{emPAI} = \frac{10^{N_{\text{observed}}}}{10^{N_{\text{observable}}}}\).

*2 Probability Based Mowse Score. Ions score is \(-10^{\text{Log}(P)}\), where P is the probability that the observed match is a random event. Individual ions scores \(>16\) indicate identity or extensive homology (p < 0.05).

doi:10.1371/journal.pone.0077118.t003
peptides were extracted once in 1% formic acid and subsequently twice in 5% formic acid and in 50% acetonitrile. Peptides were separated by nanoUPLC (nanoACQUITY UPLC, Waters, Milford, MA) and analyzed with Q-Tof micro (Waters). nanoUPLC was equipped with 50 μm Symmetry C18, 180 μmID×2 cm precolumn and 1.7 μm BEH 130 C18, 100 μmID×10 cm column. Mobile phase A was water with 0.1% formic acid whilst mobile phase B was 0.1% formic acid in acetonitrile. Using MassLynx 4.1 (Waters) the MS/MS raw data were transformed into peak lists (.pkf files) and they were searched thorough NCBInr and Swiss-Prot by using Mascot (Matrix Science, Boston, MA).

### Blood Sampling and Assays
We measured overnight fasting serum levels of total cholesterol, low density lipoprotein (LDL), cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides (L Type Wako Triglyceride H, Wako Chemical, Osaka, Japan), uric acid, creatinine (Cr), and urea nitrogen (UN). We also measured plasma glucose and HbA1c. Urinary albumin was measured in random spot urine samples by standard immuno-nephelometric assay. The urinary albumin-creatinine ratio (ACR) was calculated. Estimated glomerular filtration rate (eGFR) was calculated by equation; eGFR (ml/min/1.73 m²) = 194×Cr⁻¹.094×age⁻⁰.207 in male and eGFR (ml/min/1.73 m²) = 194×Cr⁻¹.094×age⁻⁰.207×0.739 in female [14]. By using the definition and classification of chronic kidney disease [Kidney Disease: Improving Global Outcomes (KDIGO)] [2], all patients were classified into albuminuria and GFR category. In albuminuria stages, the patients were classified into three groups; A1 (<30 mg/gCr), A2 (30–299 mg/gCr) and A3 (≥300 mg/gCr). In GFR stages, they were classified into 4 groups; G1 (>90 ml/min/1.73 m²), G2 (60–89 ml/min/1.73 m²), G3 (30–59 ml/min/1.73 m²), and G4 (15–29 ml/min/1.73 m²). Urinary excretions of fetuin-A, α1-microglobulin, and orosomucoid were measured with ELISA kit for Human Fetuin-A (BioVender, Mordice, Czech Republic), LZ Test Eiken α1-M (Eiken Chemical Co., Tokyo, Japan), and N Antiserum to Human α1-acid Glycoprotein (Siemens Healthcare Diagnostics Inc., Marburg, Germany).

#### Statistical Analysis
All data are expressed as mean ± standard deviation (SD) values in tables. Urinary levels of fetuin-A, α1-microglobulin, and orosomucoid demonstrated non-normal distribution and medians with interquartile range were indicated in box plot in Figures. Spearman correlation coefficients were used to evaluate whether urinary levels of fetuin-A, α1-microglobulin, and orosomucoid correlated with various parameters. To determine the variables independently associated with urinary levels of fetuin-A, α1-microglobulin, and orosomucoid in the patients with type 2 diabetes, multiple regression analysis was performed by including estimated glomerular filtration rate (eGFR), albumin/creatinine ratio and HDL cholesterol (HDL-C) as independent variables. Urinary levels of fetuin-A, α1-microglobulin, orosomucoid and various clinical parameters in albuminuria and GFR stages were compared by Kruskal-Wallis test. Multivariate logistic regression analysis to access the urinary fetuin-A, α1-microglobulin, orosomucoid excretions as a risk for diabetic nephropathy with microalbuminuria or with GFR<60 mL/min. P values less than

| Table 4. Comparison of various parameters in albuminuria stages of chronic kidney disease in type 2 diabetes patients (n = 85). |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                            | A1                          | A2                          | A3                          | Total                       |
| Number (male/female)        | 36 (19/17)                  | 25 (15/10)                  | 24 (15/9)                   | 85 (49/36)                  |
| Age (years)                 | 63.8±11.3                   | 61.0±12.5                   | 63.3±12.3                   | 62.9±11.3                   |
| BMI (kg/m²)                 | 24.8±5.1                    | 25.7±4.5                    | 24.2±3.9                    | 24.9±4.6                    |
| SBP (mmHg)                  | 124.0±12.6                  | 129.5±20.5                  | 126.0±19.7                  | 126.2±17.3                  |
| DBP (mmHg)                  | 73.9±10.3                   | 72.6±8.1                    | 69.1±14.4                   | 72.2±11.1                   |
| HbA1c (%)                   | 7.31±0.64                   | 7.24±0.90                   | 7.38±1.17                   | 7.31±0.87                   |
| Total protein (g/L)         | 70.4±4.3                    | 70.7±4.8                    | 66.1±6.5                    | 69.3±5.4                    |
| Albumin (g/L)               | 42.9±2.5                    | 41.2±3.2                    | 35.7±7.0                    | 40.4±5.3                    |
| Cr (μmol/L)                 | 66.4±13.3                   | 78.3±26.3                   | 144.2±70.3                  | 91.9±52.3                   |
| UN (μmol/L)                 | 5.3±1.5                     | 7.1±2.7                     | 10.0±3.8                    | 7.3±3.3                     |
| Uric acid (μmol/L)          | 305.8±61.5                  | 352.8±96.2                  | 396.2±68.0                  | 344.6±83.1                  |
| T-Chol (mmol/L)             | 5.09±0.94                   | 4.86±0.84                   | 5.06±1.14                   | 4.99±0.97                   |
| TG (mmol/L)                 | 1.65±0.92                   | 1.70±1.10                   | 2.16±1.74                   | 1.81±1.26                   |
| HDL-C (mmol/L)              | 1.49±0.41                   | 1.35±0.31                   | 1.23±0.39                   | 1.38±0.39                   |
| LDL-C (mmol/L)              | 2.85±0.81                   | 2.70±0.65                   | 2.80±0.95                   | 2.79±0.80                   |
| eGFR (ml/min)               | 74.5±13.6                   | 76.7±19.2                   | 42.4±19.0                   | 63.5±22.4                   |
| ACR (mg/gCr)                | 127.6±60                    | 114.3±72.6                  | 1424±996                    | 441.2±812                   |
| Fetuin-A (ng/gCr)           | 0.40±0.43                   | 0.60±0.53                   | 1.57±1.13                   | 0.79±0.87                   |
| α1-microglobulin (μg/gCr)   | 4.24±4.03                   | 6.30±5.12                   | 17.83±18.08                 | 8.68±11.74                  |
| Orosomucoid (ng/gCr)        | 17.5±9.1                    | 17.9±8.7                    | 91.4±87.2                   | 38.5±57.0                   |

BMI, body mass index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; Cr, serum creatinine; UN, serum urea nitrogen; T-Chol, Total cholesterol; TG, Triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; eGFR, estimated glomerular filtration ratio; ACR, albumin/creatinine ratio; *P<0.05; **P<0.01.

doi:10.1371/journal.pone.0077118.t004
0.05 were considered statistically significant. Statistical analysis was performed with IBM SPSS Statistics Base and IBM SPSS Regression (IBM, Armonk, NY).

Results
Lectin Microarray Analyses Demonstrated the Increased Binding Activity to Sia\(^{\alpha2-6}\)-Gal/GalNAc
We performed lectin microarray analyses and compared the urine samples of the healthy subjects without type 2 diabetes (n = 12) and the patients with type 2 diabetes with various stages of normoalbuminuria (n = 7), microalbuminuria (n = 5) and macroalbuminuria (n = 5). The reactivity to the many lectins, such as fucose binder (PSA, LCA, AOL, and AAL), Lac/LacNAc binder [PHA(L), ECA, RCA120, PHA(E)], \(\alpha\)- or \(\beta\)-Gal binder (BPL, ABA, PNA, ACA), chitobiose binder (DSA, LEL, STL, UDA, PWM, WGA), and \(\alpha\)- or \(\beta\)-GalNAc binder (Jacalin, WFA, MPA, VVA, DBA, SBA, PTL-I, GSL-IA4), significantly declined at the stage of macroalbuminuria (Figure 1). Among them, lectins which bind to N-glycosylation, RCA120, PHA(E), DSA, demonstrated the increased binding activity at the stage of microalbuminuria. Notably, in contrast to majority of the lectins, the binding to Sia\(^{\alpha2-6}\)-Gal/GalNAc (SNA, SSA, TJA-1) progressively increased in the albuminuria stages of diabetic nephropathy (Figure 1, red box). Since we identified specific increase in the binding activity to Sia\(^{\alpha2-6}\)-Gal/GalNAc in urine samples in the patients with diabetic nephropathy, we next screened the sialylated glycoproteins in the urine samples of diabetic nephropathy.

Fetuin-A, \(\alpha1\)-microglobulin and Orosomucoid were Identified by SSA-Agarose Column Chromatography and LC/MS-MS Analyses
SNA- and SSA-agarose were commercially available and we could isolate the glycoproteins by SSA-agarose in preliminary experiments. Thus, we performed SSA-Agarose column chromatography and the effluents were subjected to SDS-PAGE in

Figure 3. Urinary excretion of fetuin-A, \(\alpha1\)-microglobulin, orosomucoid and albumin creatinine ratio (ACR) in various stages of diabetic nephropathy (n = 85). All of the urinary excretion of sialylated glycoproteins such as fetuin-A, \(\alpha1\)-microglobulin, and orosomucoid are compared by Kruskal-Wallis test.
doi:10.1371/journal.pone.0077118.g003
Figure 2. We confirmed that the bands visualized with Coomassie Brilliant Blue staining increased in the patients with CKD stage of A3G3 compared with the patients A3G3. The effluents were subjected to LC/MS-MS and raw data of the proteins hit by Mascot program searching through NCBI nr and Swiss-Prot database were indicated in Tables 2 and 3 in the patients with CKD stages of A3G3 and A3G4, respectively. The listed proteins demonstrated the serum major proteins such as albumin, immunoglobulins, complements, α1-antitrypsin, transferrin, and haptoglobin. However, we identified three sialylated glycoproteins such as α1-microglobulin (Protein AMBP), α1-acid glycoprotein (orosomucoid) and fetuin-A (α2-HS-glycoprotein). Fetuin-A [15], α1-microglobulin [16], and orosomucoid [17] have been reported as sialylated glycoproteins and we further validated the significance of urinary excretion of sialylated glycoproteins as biomarkers for diabetic nephropathy.

Elevated Urinary Fetuin-A Excretion is a Risk for the Development of Diabetic Nephropathy

We investigated urinary excretion of sialylated glycoproteins in various stages of diabetic nephropathy (n = 85). In albuminuria stages, age, serum total protein, serum albumin, Cr, UN, uric acid, eGFR, and ACR were significantly altered by Kruskal-Wallis test (Table 5). Like albuminuria stages, the urinary excretion of fetuin-A, α1-microglobulin, and orosomucoid significantly increased in the GFR stages from G1 to G4 revealed by Kruskal-Wallis test (Table 5 and Figure 3e–h).

All of the urinary excretion of fetuin-A, α1-microglobulin, and orosomucoid positively correlated with Cr, UN and ACR and negatively correlated with serum albumin, HDL-C and eGFR with statistically significant differences (Table 6 and Figure 4). The linear regression analyses were followed by a multiple regression analysis using the urinary excretion of fetuin-A, α1-microglobulin, and orosomucoid as the dependent variables to further analyze the significant predictors (Table 6). eGFR, ACR and HDL-C were used as independent variables. eGFR and ACR independently and significantly predicted urinary excretion of fetuin-A and α1-microglobulin. For urinary excretion of orosomucoid, ACR and HDL-C were significantly determinants in multiple regression models in Table 7. Finally, multivariate logistic regression analysis was employed to assess three urinary sialylated glycoproteins as a risk for diabetic nephropathy with microalbuminuria or GFR<60 mL/min. We used the forward stepwise method and the variable whose addition causes the largest statistically significant change in −2 Log Likelihood is added to the model. The final models are indicated in Tables 8 and only fetuin-A was demonstrated as a risk factor for both microalbuminuria and reduction of GFR in diabetic nephropathy with the odds ratio (95% confidence intervals) of 4.721 (1.881–11.844) and 3.739 (1.785–7.841), respectively.
Table 6. Simple correlation of urinary sialylated glycoprotein excretions with various clinical parameters in the patients with type 2 diabetes (n = 85).

|                  | Fetuin-A (ng/gCr) | α1-microglobulin (µg/gCr) | Orosomucoid (ng/gCr) |
|------------------|-------------------|--------------------------|---------------------|
| Age (years)      | R = 0.009, p = 0.937 | R = 0.123, p = 0.261    | R = -0.008, p = 0.944 |
| BMI (kg/m²)      | R = -0.139, p = 0.205 | R = -0.067, p = 0.541    | R = -0.032, p = 0.770  |
| SBP (mmHg)       | R = 0.043, p = 0.693  | R = -0.005, p = 0.964    | R = 0.103, p = 0.348   |
| DBP (mmHg)       | R = 0.145, p = 0.186  | R = -0.214, p = 0.049*   | R = -0.027, p = 0.807*  |
| HbA1c (%)        | R = 0.113, p = 0.307  | R = 0.110, p = 0.318    | R = 0.056, p = 0.612   |
| Total protein (g/L) | R = -0.261, p = 0.017* | R = -0.275, p = 0.012* | R = -0.213, p = 0.053 |
| Albumin (g/L)    | R = -0.377, p = 4.36 x 10^{-4} | R = -0.376, p = 4.67 x 10^{-4} | R = -0.394, p = 2.28 x 10^{-4} |
| Cr (µmol/L)      | R = 0.368, p = 5.23 x 10^{-4} | R = 0.388, p = 2.40 x 10^{-4} | R = 0.399, p = 1.53 x 10^{-4} |
| UN (µmol/L)      | R = 0.405, p = 1.31 x 10^{-4} | R = 0.439, p = 2.96 x 10^{-4} | R = 0.363, p = 6.85 x 10^{-4} |
| Uric acid (µmol/L) | R = 0.079, p = 0.474 | R = 0.073, p = 0.509 | R = 0.295, p = 0.006** |
| T-Chol (mmol/L)  | R = -0.099, p = 0.372 | R = -0.080, p = 0.471 | R = 0.062, p = 0.576 |
| TG (mmol/L)      | R = 0.060, p = 0.582 | R = 0.055, p = 0.615 | R = 0.186, p = 0.088 |
| HDL-C (mmol/L)   | R = -0.313, p = 0.004** | R = -0.258, p = 0.017* | R = -0.244, p = 0.025* |
| LDL-C (mmol/L)   | R = -0.007, p = 0.948 | R = -0.043, p = 0.697 | R = 0.067, p = 0.544 |
| eGFR (mL/min)    | R = -0.395, p = 1.80 x 10^{-4} | R = -0.472, p = 5.23 x 10^{-4} | R = -0.431, p = 3.90 x 10^{-4} |
| ACR (mg/gCr)     | R = 0.548, p = 5.76 x 10^{-4} | R = 0.466, p = 7.02 x 10^{-4} | R = 0.652, p = 1.40 x 10^{-11}** |

BMI, body mass index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; Cr, serum creatinine; UN, serum urea nitrogen; T-Chol, Total cholesterol; TG, Triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; eGFR, estimated glomerular filtration ratio; ACR, albumin/creatinine ratio;

*p < 0.05; **p < 0.01.

doi:10.1371/journal.pone.0077118.t006

Figure 4. Simple correlation of urinary excretion of fetuin-A, α1-microglobulin, orosomucoid with estimated glomerular filtration ratio (eGFR) and urinary albumin creatinine ratio (ACR) in the patients with diabetic nephropathy (n = 85). Spearman correlation coefficients are used to evaluate whether urinary levels of fetuin-A, α1-microglobulin, and orosomucoid correlate with eGFR and ACR.
doi:10.1371/journal.pone.0077118.g004
Glycans have important roles in living organisms with their structural diversity; however, glycan profiling studies have not been extensively performed because it is technically challenging. Recently, the genome-wide association study identified hepatocyte nuclear factor 1-α (HNF1A) as a key regulator of fucosylation and the DG9-glycan index, which is the ratio of fucosylated to nonfucosylated triantennary glycans, display altered fucosylation of N-linked glycans on plasma proteins. Thus, the glycan biomarkers could improve the efficiency of a diagnosis of HNF1A-MODY [18]. In diabetic nephropathy, Ahn J.M. et al. performed glycan profile of plasma samples from normal subjects and the patients with diabetes. They captured glycoproteins by multi-lectin affinity chromatography and trypsin-digested glyco-proteins were subjected to the analysis by LC-MS/MS [19].

However, no other studies have been reported to survey the glycan profile of the urine samples so far, and we believe that the current investigation is the first study to perform glycan profiling of urines samples from the patients with diabetic nephropathy. As a result, increased sialylated glycoproteins in urine samples of diabetic nephropathy may be due to the alteration in the permselectivities of glomerular capillary, since sialylated glycoproteins are characterized by negative charge.

Table 7. Multiple linear regression analysis using urinary sialylated glycoprotein excretions as dependent variables in the patients with type 2 diabetes (n=85).

| Dependent variable | Independent variable | Unstandardized coefficient | Standardized coefficient | t value | P value | Adjusted R² |
|--------------------|----------------------|-----------------------------|--------------------------|---------|---------|-------------|
| Fetuin-A (ng/gCr)  | eGFR (mL/min)        | -0.076                      | -0.196                   | -1.813  | 0.074   | 0.335       |
| HDL-C (mmol/L)     | ACR (mg/gCr)         | 0.004                       | 0.395                    | 3.645   | 0.000   | 0.473       |
| s1-microglobulin   | eGFR (mL/min)        | -0.138                      | -0.263                   | -2.617  | 0.011   | 0.423       |
| HDL-C (mmol/L)     | ACR (mg/gCr)         | 0.007                       | 0.461                    | 4.560   | 0.000   | 0.523       |
| Orosomucoid (ng/gCr)| eGFR (mL/min)       | -0.136                      | -0.053                   | -0.642  | 0.523   | 0.605       |
| HDL-C (mmol/L)     | ACR (mg/gCr)         | 0.049                       | 0.703                    | 8.405   | 0.000   | 1.19×10⁻¹²**|

Discussion

Estimated glomerular filtration rate (eGFR), albumin/creatinine ratio and HDL cholesterol (HDL-C) are used as independent variables in stepwise multiple linear regression analysis in model 1. In model 2, all parameters are included in the analysis.

*p<0.05; **p<0.01.
doi:10.1371/journal.pone.0077118.t007

Table 8. Stepwise multivariate logistic regression analysis to assess the urinary sialylated glycoprotein excretions as a risk for diabetic nephropathy with microalbuminuria or glomerular filtration rate (GFR)<60 ml/min.

| Risk factor for microalbuminuria | B         | Standard error | p       | Odds ratio (95% confident intervals) | Predictive accuracy |
|--------------------------------|-----------|----------------|---------|------------------------------------|---------------------|
| Fetuin-A (ng/gCr) (1SD increments) | 1.784     | 0.539          | 9.424×10⁻⁴** | 4.721 (1.881–11.844)               | 74.1%               |
| Risk factor for GFR<60 mL/min   | B         | Standard error | p       | Odds ratio (95% confident intervals) | Predictive accuracy |
| Fetuin-A (ng/gCr) (1SD increments) | 1.516     | 0.434          | 4.755×10⁻⁴** | 3.739 (1.785–7.841)               | 72.9%               |

*p<0.01.
doi:10.1371/journal.pone.0077118.t008
the early stages of the disease process, while albumin excretion was still in the normal range [25]. Thus, it may serve as an early marker for tubular damages in diabetic nephropathy and may precede albumin excretion to the urine [25–27]. Low molecular weight markers of tubular dysfunction such as α1-microglobulin, therefore, appear as markers of renal dysfunction that may complement markers of glomerular dysfunction such as albumin [7]. Orosomucoid, a 1-acid glycoprotein with 41 kDa, is an acute-phase protein and the serum concentrations correlated with low-grade inflammation in the patients with diabetes [28,29]. Urine excretion of orosomucoid was increased in the patients with diabetes and normoalbuminuria and it correlated with markers of inflammation such as CRP [29–31] and markers for endothelial dysfunction [32]. Type 2 diabetic patients with elevated urinary orosomucoid excretion exhibited normal glomerular and tubular function, suggesting the possibility of local renal production of orosomucoid due to chronic low-grade inflammation rather than hyperfiltration [33].

Fetuin-A has been principally studied as an inhibitor for ectopic calcium deposition in the renal field and it is also an important promoter for insulin resistance. Fetuin-A, a liver secretory glycoprotein with 64 kDa, has been shown that it acts as carrier of free fatty acids (FFAs) and they are the intrinsic ligands for Toll-like receptor 4 (TLR4), which induces adipose tissue inflammation and insulin resistance [34]. Fetuin-A binds to the residues of Leu100-Gly123 and Thr493-Thr516 of TLR4 through the terminal galactoside moiety [34]. Thus, FFA-Fetuin-A induced TLR4 activation is very important in the lipid-induced inflammation and insulin resistance and type 2 diabetes. In addition, fetuin-A and adiponectin mediate the crosstalk between adipose tissues, liver and kidney. Fetuin-A suppresses mRNA expression of adiponectin in cultured human adipocytes and treatment of wild-type mice with fetuin-A lowered serum adiponectin levels [35]. Higher fetuin-A and lower adiponectin levels may contribute to the development of insulin resistance, diabetes and subsequent obesity-related CKD and diabetic nephropathy [36]. Serum concentration of fetuin-A in type 2 diabetes patients has been reported and they positively correlated with macrovascular late complications in high-risk type 2 diabetes patients, while no association with metabolic status or microvascular complications [37]. Recent study indicated that serum fetuin-A is lower in microalbuminuria patients compared with normo- and macroalbuminuric patients [38]. In other studies, lower serum levels of fetuin-A are associated with peripheral arterial disease in patients with type 2 diabetes [39] and serum fetuin-A levels are negatively associated with atherosclerotic calcified plaques [40]. Thus, the significance of serum fetuin-A levels is controversial whether it is a good marker for diabetic micro- and macrovascular complications. Unfortunately, we failed to detect changes in binding activities to various lectins in the sera from the patients with various stages of diabetic nephropathy (data not shown), we did not get a chance to measure the serum levels of fetuin-A. However, we demonstrated that the urinary excretion of fetuin-A is a candidate for the biomarker to predict the progression of diabetic nephropathy. Although two previous published studies identified fetuin-A in urine samples of the patients with diabetic nephropathy, the quantifications were limited to inaccurate estimations by fluorescence 2-D differential in-gel electrophoresis [41] and capillary electrophoresis coupled to mass spectrometry [42]. In contrast to previous studies, we firstly used stable ELISA kit to quantify the urinary excretion of fetuin-A. Urinary concentration of fetuin-A may be depending on the production from the liver, alterations in permeability through glomerular basement membrane by capillary damages and changes in tubular reabsorption. Higher excretion of fetuin-A into urine has been reported to reflect the insulin resistance and inflammatory responses in obesity and type 2 diabetes [43] and it may reflect the increase in the serum levels of fetuin-A and alterations in the changes in the permeability of glomerular capillaries. Fetuin-A is reported to pass through the slit diaphragm and re-introduced to proximal tubular cells by megalin-mediated endocytosis [44]. Zhou et al. also reported that urinary exosomal fetuin-A was increased in the rats treated with cisplatin injection and in the ICU patients with acute kidney injury [45]. Thus, an alternative explanation for increased urinary fetuin-A excretion in diabetic nephropathy could be due to the tubular injury. In our study, multivariate regression analysis indicated that higher urinary fetuin-A excretion demonstrated a higher risk for the development of microalbuminuria and reduction of renal function and future cohort study is required to further confirm this notion.

Conclusions

In summary, the glycan profiling studies using urine samples from the patients with diabetic nephropathy is useful to identify the new biomarkers to predict the progression of diabetic nephropathy. We demonstrated that global reduction of the bindings to lectins, such as fucose, Lac/LacNA, α- or β-Gal, chitobiose, and α- or β-GalNAc binders in urine samples of diabetic nephropathy at macroalbuminuria stage, and in contrast increased binding activity to Siaα2-6-Gal/GalNAc binders. Further, we identified three sialylated glycoproteins such as α1-microglobulin (Protein AMBP), α1-acid glycoprotein (orosomucoid) and fetuin-A (α2-HS-glycoprotein) by SSA-Agarose column chromatography and LC/MS/MS analysis. Finally, we have newly shown that higher urinary excretion of fetuin-A is a risk factor for both microalbuminuria and reduction of GFR in diabetic nephropathy.

Author Contributions

Wrote the paper: JW KI HM. Designed and performed most of the experiments: KI JW. Recruited the patients: JE AN ST KM DO TT AK AT II KH. Performed lectin microarray analysis: MY TO. Conceived the study: JW KI HM.

References

1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, et al. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383–393.

2. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, et al. (2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 80: 17–28.

3. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, et al. (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20: 1813–1821.

4. Schmiede RE, Mann JF, Schumacher H, Gao P, Mancia G, et al. (2011) Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 22: 1353–1364.

5. Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, et al. (2007) Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 18: 1353–1361.

6. Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, et al. (2011) Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 54: 2976–2986.

7. Matheson A, Willcox MD, Flanagan J, Walsh BJ (2010) Urinary biomarkers for diabetes -1 acid glycoprotein with 41 kDa, is an acute-phase factor for both microalbuminuria and reduction of GFR in diabetic nephropathy.
9. Zurbig P, Jerums G, Hovind P, Maciasse RJ, Mischak H, et al. (2012) Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 61: 3304–3313.

10. Gu W, Zou LX, Shan PF, Chen YD (2008) Analysis of urinary proteomic patterns for diabetic nephropathy by ProteinChip. Proteomics Clin Appl 2: 744–750.

11. Marshall S, Bacote Y, Trauzinger RK (1991) Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexoseamine biosynthesis in the induction of insulin resistance. J Biol Chem 266: 4706–4712.

12. Arias ER, Kim J, Cartee GD (2004) Prolonged incubation in PUGNAC reagent in increased protein O-Linked glycosylation and insulin resistance in rat skeletal muscle. Diabetes 53: 921–930.

13. Kuno A, Uchiyama N, Koseki-Kuno S, Ebe Y, Takashima S, et al. (2005) Evansen-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling. Nat Methods 2: 451–456.

14. Matsuo S, Imai E, Horio M, Yuzada Y, Tomita K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982–992.

15. Saroha A, Kumar S, Chatterjee BP, Chatterjee A, Das HR (2012) Jacalin bound plasma O-glycoproteome and reduced sialylation of alpha 2-HS glycoprotein (A2HSG) in rheumatoid arthritis patients. PLoS One 7: e46374.

16. Bratt T, Olson H, Sjoberg EM, Jergil B, Akerstrom B (1993) Cleavage of the alpha 1-microglobulin-bikumin precursor is localized to the Golgi apparatus of rat liver cells. Biochim Biophys Acta 1157: 147–154.

17. Bierhuizen MF, De Wit M, Goerss CA, Fervaleta W, Koelman G, et al. (1988) Glycosylation of three molecular forms of human alpha 1-acid glycoprotein having different interactions with concanavalin A. Variations in the occurrence of dis., tris. and tetraantennary glycans and the degree of sialylation. Eur J Biochem 175: 387–394.

18. Thanabalasingham G, Huffman JE, Katlla JJ, Novokmet M, Rudan I, et al. (2013) Mutations in HNF1A result in marked alterations of plasma glycan profile. Diabetes 62: 1329–1337.

19. Ahn JM, Kim BG, Yu MH, Lee IK, Cho JY (2010) Identification of diabetic nephropathy-selective proteins in human plasma by multi-lectin affinity chromatography and LC-MS/MS. Proteomics Clin Appl 4: 644–653.

20. Waters PJ, Flynn MD, Penkow CA, Corrall RJ, Greenwood RJ, et al. (1995) Decreased sialidase activity in mononuclear leucocytes of type 1 diabetic subjects: relationship to diabetic complications and glycaemic control. Diabet Med 12: 670–673.

21. Nele O, Lagundzin D, Masnikosa R (2012) Posttranslational modifications of the insulin-like growth factor-binding protein 3 in patients with type 2 diabetes mellitus assessed by affinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 904: 93–98.

22. Lee CL, Chia PC, Pang PC, Chia IK, Lee KF, et al. (2011) Glycosylation failure extends to glycoproteins in gestational diabetes mellitus: evidence from reduced alpha2-6 sialylation and impaired immunomodulatory activities of pregnancy-related glycolipid-alpha. Diabetes 60: 909–917.

23. Kido T, Honda R, Yamada Y, Tsurutani I, Ishizaki M, et al. (1985) alpha 1-Microglobulin determination in urine for the early detection of renal tubular dysfunctions caused by exposure to cadmium. Toxicol Lett 24: 195–201.

24. Hong CV, Hughes K, Chia KS, Ng V, Lang SL (2003) Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care 26: 338–342.

25. Pfeiderer S, Zimmerhach LB, Kanne R, Marnz F, Schuler G, et al. (1993) Renal proximal and distal tubular function is attenuated in diabetes mellitus type 1 as determined by the renal excretion of alpha 1-microglobulin and Tamm-Horsfall protein. Clin Invest 71: 972–977.

26. Penders J, Delanghe JR (2004) Alpha 1-microglobulin: clinical laboratory aspects and applications. Clin Chim Acta 346: 107–118.

27. Galanti LM, Jamart J, Dell’omo J, Doucier J (1996) Comparison of urinary excretion of albumin, alpha 1-microglobulin and retinol-binding protein in diabetic patients. Diabetes Metab 22: 324–330.

28. Christiansen MS, Holmee E, Magil E, Feldt-Rasmussen B (2002) Orosomucoid in urine predicts cardiovascular and over-all mortality in patients with Type II diabetes. Diabetologia 45: 115–120.

29. Narita T, Sasaki H, Hosoba M, Miura T, Yoshikawa N, et al. (2004) Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normalalbuminuric type 2 diabetic patients. Diabetes Care 27: 1176–1181.

30. Jiang H, Gnan G, Zhang R, Liu G, Liu H, et al. (2009) Increased urinary excretion of orosomucoid is a risk predictor of diabetic nephropathy. Nephrology (Carlton) 14: 332–337.

31. Ito S, Tsuda A, Momotou T, Igarashi K, Kasahara S, et al. (1989) Urinary orosomucoid excretion rate in patients with non-insulin-dependent diabetes mellitus. Acta Endocrinol (Copenb) 120: 584–589.

32. Christiansen MS, Jversen K, Larsen CT, Goeetz JP, Holmee E, et al. (2009) Increased urinary orosomucoid excretion: a proposed marker for inflammation and endothelial dysfunction in patients with type 2 diabetes. Scand J Clin Lab Invest 69: 272–281.

33. Christiansen MS, Hasse D, Ebbom P, Hesse U, Damm P, et al. (2010) Increased urinary orosomucoid excretion predicts preeclampsia in pregnant women with pregestational type 1 diabetes. Diabetes Res Clin Pract 89: 16–21.

34. Pal D, Das Gupta S, Kundu R, Maina S, Das G, et al. (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med.

35. Heineje AM, Staiger H, Wex C, Machicoa F, Frische A, et al. (2008) Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One 3: e1765.

36. JX, JH, Sharma K (2010) Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 21: 406–410.

37. Roos M, Olokonou D, von Kynatten M, Lupa PB, Heemann U, et al. (2010) Associations of fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. Cardiovasc Diabetol 9: 48.

38. Koluman BU, Muthay R, Derici UB, Aminoy T, Senlik Z, et al. (2013) Association between osteoprotegerin, fetuin-A, carotid intima media thickness, and urinary albumin excretion in Type 2 diabetes. Clin Nephrol 80: 9–16.

39. Eraso LH, Givwala N, Qasim AN, Mehta NN, Dlugoh R, et al. (2010) Association of lower plasma fetuin-a levels with peripheral arterial disease in type 2 diabetes. Diabetes Care 33: 408–410.

40. Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, et al. (2010) Proteomic analysis of human serum: Fetuin-A and its association with osteoporosis in diabetes mellitus. J Diabetes Res 2010: 302483.

41. Rao PV, Lu X, Standley M, Pettee P, Nellema G, et al. (2007) Proteinic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 30: 629–637.

42. Roscioni SS, de Zeeve D, Hellemans ME, Mischak H, Zurbig P, et al. (2013) A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 56: 259–267.

43. Jung CH, Kim BY, Kim CH, Kang SK, Jung SH, et al. (2013) Associations of serum fetuin-A levels with insulin resistance and vascular complications in patients with type 2 diabetes. Diab Vasc Dis Res.

44. Matsui I, Hamano T, Mikami S, Inoue K, Shimomura A, et al. (2013) Retention of Fetuin-A in renal tubular lumen protects the kidney from nephrocalcinosis in rats. Am J Physiol Renal Physiol 304: F751–760.

45. Zhou H, Putkun A, Aponte A, Yuan PH, Hallford JD, et al. (2006) Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int 70: 1847–1857.